(Q38075818)

28 August 2017

1 reference

title

PCSK9 Inhibitors: potential in cardiovascular therapeutics (English)

1 reference

28 August 2017

Rose Q Do

1

1 reference

28 August 2017

Robert A Vogel

series ordinal

2

1 reference

28 August 2017

Gregory G Schwartz

series ordinal

3

1 reference

28 August 2017

1 March 2013

1 reference

Current cardiology reports

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

3

1 reference

28 August 2017

345

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-012-0345-z

28 August 2017

0 references

cites work

Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Beyond LDL cholesterol, a new role for PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Adnectins: engineered target-binding protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0345-Z

High-dose atorvastatin after stroke or transient ischemic attack

21 January 2018

1 reference

12 December 2020

Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)

1 reference

12 December 2020

Statins for the treatment of dementia

1 reference

12 December 2020

The solution structure of a locked nucleic acid (LNA) hybridized to DNA

1 reference

12 December 2020

PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.

1 reference

12 December 2020

Antibodies to PCSK9: a superior way to lower LDL cholesterol?

1 reference

12 December 2020

The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population

1 reference

12 December 2020

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

12 December 2020

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

12 December 2020

Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells

1 reference

12 December 2020

Effect on hematologic risk factors for coronary heart disease of a cholesterol reducing diet.

1 reference

12 December 2020

The effect of low- and high-density lipoprotein cholesterol on steroid hormone production and ACTH-induced differentiation of rat adrenocortical cells in primary culture

1 reference

12 December 2020

10.1007/S11886-012-0345-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference